If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 251 - 260 of 281

BLAST MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML

What are the good and bad effects of adding the study drug pembrolizumab to the usual treatment for patients with chronic myelogenous leukemia (CML)? The usual approach is defined as care most people get for CML and includes treatment with tyrosine kinase inhibitors (TKIs).
Protocol No